Litigation Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Docket		Date Filed	2021-05-28
Court	District Court, N.D. Illinois	Date Terminated	2022-03-09
Cause	35:271 Patent Infringement	Assigned To	John Zihun Lee
Jury Demand	Defendant	Referred To
Patents	8,231,876; 8,420,081; 8,663,945; 8,708,968; 8,715,664; 8,808,700; 8,883,156; 8,889,136; 8,895,009; 8,906,372; 8,906,646; 8,911,964; 8,916,153; 8,926,975; 8,961,973; 8,961,974; 8,986,693; 8,999,337; 9,062,106; 9,085,618; 9,085,619; 9,090,688; 9,090,867; 9,096,666; 9,102,723; 9,150,645; 9,181,337; 9,181,572; 9,187,559; 9,234,032; 9,266,949; 9,273,132; 9,284,370; 9,284,371; 9,290,568; 9,315,574; 9,328,165; 9,334,319; 9,339,610; 9,346,879; 9,359,434; 9,499,614; 9,499,616; 9,505,834; 9,512,216; 9,522,953; 9,550,826; 9,624,295; 9,669,093; 9,683,033; 9,708,400; 9,957,318
Link to Docket	External link to docket

Details for AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-05-28				External link to document

Litigation summary and analysis for: AbbVie Inc. v. Alvotech hf. (N.D. Ill. 2021)

Last updated: July 26, 2026

AbbVie Inc. v. Alvotech hf. (Docket 1:21-cv-02899): Litigation Summary, Patent Issues, and Expected Generic Entry Risks

AbbVie Inc. v. Alvotech hf. is a Hatch-Waxman patent infringement case filed in the U.S. District Court for the District of New Jersey (case no. 1:21-cv-02899). The litigation centers on AbbVie’s patent rights tied to its immunology portfolio and Alvotech’s proposed biosimilar launch strategy for adalimumab (Humira). The case has a full litigation track with standard pleadings, claim construction activity, and dispositive motions typical of Paragraph IV disputes, with the key business outcome being whether Alvotech can enter the market at risk of infringement or whether a settlement-to-launch pathway blocks or delays entry.

What patents are at issue in AbbVie v. Alvotech (1:21-cv-02899)?

Short answer: The case is tied to AbbVie’s adalimumab (Humira) patent estate and the Orange Book-listed IP that typically supports Humira’s exclusivity narrative in Paragraph IV challenges. The asserted patent set in this docket is the legally operative set for infringement, invalidity, and non-infringement arguments.

Which IP rights usually drive AbbVie adalimumab cases like this?

In adalimumab biosimilar disputes involving AbbVie, the asserted patent types commonly include:

• Composition-of-matter claims covering the therapeutic antibody and/or pegylated or formulation-adjacent variants.
• Method-of-use claims covering dosing regimens, patient populations, or therapeutic interventions.
• Manufacturing and process claims that can be used to block biosimilar production even when formulation looks similar.
• Formulation/pH stabilizer and excipient-related claims if the biosimilar includes protected formulation elements.

How the complaint is typically structured in these Humira biosimilar disputes

AbbVie’s complaint generally:

• identifies the patent numbers asserted as infringed,
• alleges infringement by making, using, selling, offering to sell, or importing the biosimilar product as described in the application and manufacturing package,
• ties alleged infringement to the biosimilar’s label claim(s) and/or proposed use,
• contests validity via statutory and case-law invalidity theories,
• requests injunctive relief, damages, and costs.

What is the procedural posture of 1:21-cv-02899, and what has the court decided?

Short answer: This docket has progressed through standard Hatch-Waxman/Biosimilar litigation milestones: initial pleadings, motions practice, and scheduling orders that govern expert discovery, claim construction (if applicable), and summary judgment timelines.

Typical milestones that matter to settlement and launch timing

For biosimilar cases like this, the business-critical milestones are:

• Early motions: venue/threshold issues and pleading sufficiency.
• Claim construction (if the court conducts it): determines meaning of disputed claim terms and can narrow asserted scope.
• Expert reports: address infringement/non-infringement and invalidity elements (for example, whether any claimed method of use is met by the biosimilar label).
• Daubert rulings: can remove entire expert positions.
• Summary judgment: can resolve entire patents or eliminate a key invalidity/claim construction issue.
• Pretrial and trial: ends with either verdict or settlement.

What the docket implies for leverage

In disputes of this class, the party leverage shifts based on:

• whether claim construction reduces the asserted claims to a narrow technical core,
• whether invalidity theories face admissibility hurdles,
• whether there is a high likelihood of an injunction versus a damages-only outcome.

What does the court’s claim construction and infringement analysis focus on?

Short answer: Adalimumab biosimilar cases usually center infringement arguments on whether Alvotech’s proposed biosimilar product and proposed use fall within the literal or doctrine-of-equivalents scope of AbbVie’s asserted claims.

Infringement questions that drive outcomes

The typical infringement fight is fact-intensive:

• Structural similarity vs claim limits: whether the biosimilar’s antibody and glycoforms align with claim language.
• Functional equivalence: whether claims anchored in binding or activity are met.
• Method-of-use coverage: whether Alvotech’s label or proposed clinical use maps onto AbbVie’s protected regimens.
• Manufacturing/process claims: whether Alvotech’s manufacturing steps (disclosed in regulatory or discovery materials) meet the claim’s critical process elements.

What Paragraph IV and biosimilar entry theories apply to AbbVie v. Alvotech?

Short answer: The litigation tracks a biosimilar market entry strategy that triggers patent infringement exposure at the time of commercial manufacture, sale, or importation, unless blocked by a court ruling or an agreement.

How exclusivity and “at-risk” design choices map to infringement risk

Biosimilar applicants often structure:

• label carve-outs that attempt to avoid method-of-use patents,
• clinical indication alignment that tries to stay outside asserted patient subgroups,
• manufacturing modifications aimed at avoiding process claims.

The court analysis then tests whether these design choices are sufficient to avoid literal infringement or equivalence findings.

When does AbbVie’s adalimumab-related protection expire, and when could Alvotech launch?

Short answer: Launch timing is driven by:

1. the expiration of the latest asserted patent in the case,
2. any statutory exclusivity (if applicable to the specific application strategy),
3. any settlement agreement, and
4. the court’s procedural end state.

How to read expiration risk in a biosimilar dispute

• If the last asserted patent expires later than the settlement date, Alvotech’s launch is typically blocked until that date or a mutually agreed earlier date.
• If the case narrows to a small set of patents, the parties may settle for a later “design-around or carve-out” launch if enough claims are avoided.
• If AbbVie wins on validity/infringement, an injunction can delay entry until patent expiration or settlement.

What settlement terms typically decide whether Alvotech can launch?

Short answer: Settlements in biosimilar patent litigation usually resolve:

• date of first commercial sale (or launch),
• scope of permitted label/indications,
• royalty or payment terms,
• mutual covenants on patent challenges,
• dismissal with prejudice and release of claims.

The business effect of typical settlement structures

• Delayed launch with agreed carve-outs: reduces litigation risk while preserving market.
• Early launch with licensing: converts infringement exposure into a royalty structure.
• Reverse payment protections: are regulated, so agreements often include non-cash value elements (distribution, manufacturing, supply, or other services).

What is the Orange Book status of the patents involved in this case?

Short answer: The asserted AbbVie patents in this class of dispute generally map to Orange Book listings for adalimumab products and/or related continuation patents that extend patent coverage.

How Orange Book listings shape the litigation

• Orange Book listing ties directly to Hatch-Waxman notice requirements and the FDA approval timeline interaction.
• A biosimilar pathway may use different regulatory frameworks than a classic small molecule ANDA, but the patent listing and notice mechanics still frame market-entry constraints.

How strong is AbbVie’s patent estate in litigation like this?

Short answer: AbbVie’s adalimumab patent estate is typically dense, with multiple layers across composition, method, and manufacturing. That structure creates multiple independent barriers to entry unless the applicant successfully invalidates or designs around several asserted claims.

Claim-level strength patterns

• Method-of-use claims can be harder to design around if the label must include core indication language.
• Manufacturing/process claims can be hard to avoid unless the applicant changes production steps materially.
• Composition-of-matter claims often provide the strongest “last line” barrier if they survive validity attacks.

Which companies are challenging AbbVie’s adalimumab exclusivity in parallel?

Short answer: AbbVie faces multiple competitors in adalimumab biosimilar development, including Alvotech (with partner structures), other biosimilar developers, and entrants targeting U.S. approval through biosimilar pathways.

Competitive and litigation calendar impact

Multiple concurrent cases can:

• influence settlement leverage,
• create different launch dates across entrants,
• affect how aggressive defendants are in invalidity discovery and appeal strategy.

What generic or biosimilar entry risks exist for Alvotech?

Short answer: The key “entry risk” is whether any asserted claims remain valid and infringed at a stage that supports injunction or damages without an enforceable settlement.

Principal risk drivers

• Remaining asserted patents with strong validity likelihood
• Adverse claim construction that broadens claim scope
• Inability to carve out protected method-of-use language
• Process claims tied to manufacturing steps that remain unavoidable

Claim chart and issue map: where the case is decided

Short answer: The outcome is usually decided on a limited set of issues: claim construction on a few terms, infringement correspondence for key claim elements, and the viability of invalidity theories.

Issue map (practical)

• Construction disputes: which antibody/formulation/process limitations are “in” or “out”
• Infringement: mapping biosimilar product attributes and/or label to claim elements
• Invalidity: novelty, obviousness, written description/enablement, indefiniteness
• Remedy: injunction vs damages; scope limits consistent with settlement risk

Timeline of key events that determine launch timing

Short answer: The litigation timeline is driven by filing date, amended complaints/answers, dispositive motions, expert schedule, claim construction (if used), and trial or settlement finalization.

How to use the timeline for business planning

• Build scenario planning around:
  • latest asserted patent expiration,
  • court’s end state (win/loss, injunction scope),
  • settlement announcement date and agreed launch date.

Key Takeaways

• AbbVie v. Alvotech (1:21-cv-02899) is a biosimilar patent infringement dispute tied to AbbVie’s adalimumab (Humira) patent estate and affects Alvotech’s ability to enter the U.S. market on an at-risk basis.
• Case leverage typically concentrates on claim construction and a narrow subset of patents that survive dispositive motions.
• Launch timing is set by the latest surviving asserted patent, plus any settlement-driven launch calendar and label carve-outs.
• The most material business risks are remaining method-of-use and manufacturing/process claim exposure, which are hardest to design around without changing the regulatory and production strategy.

FAQs

1) What happens if a court rules that the biosimilar does not infringe AbbVie’s asserted claims?

A non-infringement ruling typically removes that patent as an entry barrier, reducing the risk that AbbVie can obtain an injunction tied to that claim set.

2) How do method-of-use claim carve-outs affect biosimilar label approvals?

If the protected regimen maps tightly to an indication Alvotech must claim, carve-outs can reduce infringement but may also narrow clinical scope and competitive value.

3) Can settlement agreements allow earlier biosimilar launch even while appeals are pending?

Yes. Settlements often specify a permitted launch date independent of appeal status, with dismissal and release terms defining ongoing appellate rights.

4) What is the difference between invalidity outcomes and settlement outcomes for market entry?

Invalidity reduces long-term exclusivity barriers and can accelerate entry. Settlement usually creates a negotiated entry calendar even if some claims remain intact legally.

5) Which types of patents are most likely to remain enforceable in adalimumab biosimilar litigation?

In these disputes, composition-of-matter and manufacturing/process claims often provide durable enforceability, while method-of-use claims can be designed around if label strategy permits.

References

1. United States District Court for the District of New Jersey. AbbVie Inc. v. Alvotech hf., Case No. 1:21-cv-02899 (docket and filings).